Levomilnacipran is the (1S,2R)-enantiomer of milnacipran and a serotonin-noradrenaline reuptake inhibitor that is used in the treatment of depression. It was first FDA approved on the 25th of July 2013.
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
|Antidepressants (ATC: N06A)|